Literature DB >> 27810898

MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) Interaction Disruptor Sensitizes Insulin Signaling in Skeletal Muscle.

Hyun Lee1, Jung-Jin Park1, Nga Nguyen1, Jun Sub Park1, Jin Hong1, Seung-Hyeob Kim1, Woon Young Song2, Hak Joong Kim2, Kwangman Choi3, Sungchan Cho3, Jae-Seon Lee4, Bong-Woo Kim5, Young-Gyu Ko6.   

Abstract

Mitsugumin 53 (MG53) is an E3 ligase that interacts with and ubiquitinates insulin receptor substrate-1 (IRS-1) in skeletal muscle; thus, an MG53-IRS-1 interaction disruptor (MID), which potentially sensitizes insulin signaling with an elevated level of IRS-1 in skeletal muscle, is an excellent candidate for treating insulin resistance. To screen for an MID, we developed a bimolecular luminescence complementation system using an N-terminal luciferase fragment fused with IRS-1 and a C-terminal luciferase fragment fused with an MG53 C14A mutant that binds to IRS-1 but does not have E3 ligase activity. An MID, which was discovered using the bimolecular luminescence complementation system, disrupted the molecular association of MG53 with IRS-1, thus abolishing MG53-mediated IRS-1 ubiquitination and degradation. Thus, the MID sensitized insulin signaling and increased insulin-elicited glucose uptake with an elevated level of IRS-1 in C2C12 myotubes. These data indicate that this MID holds promise as a drug candidate for treating insulin resistance.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  diabetes; drug discovery; insulin receptor substrate 1 (IRS-1); insulin resistance; skeletal muscle

Mesh:

Substances:

Year:  2016        PMID: 27810898      PMCID: PMC5207173          DOI: 10.1074/jbc.M116.754424

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Nonmuscle myosin IIA facilitates vesicle trafficking for MG53-mediated cell membrane repair.

Authors:  Peihui Lin; Hua Zhu; Chuanxi Cai; Xianhua Wang; Chunmei Cao; Ruiping Xiao; Zui Pan; Noah Weisleder; Hiroshi Takeshima; Jianjie Ma
Journal:  FASEB J       Date:  2012-01-17       Impact factor: 5.191

2.  Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair.

Authors:  Xianhua Wang; Wenjun Xie; Yi Zhang; Peihui Lin; Liang Han; Peidong Han; Yanru Wang; Zheng Chen; Guangju Ji; Ming Zheng; Noah Weisleder; Rui-Ping Xiao; Hiroshi Takeshima; Jianjie Ma; Heping Cheng
Journal:  Circ Res       Date:  2010-05-13       Impact factor: 17.367

3.  Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy.

Authors:  Noah Weisleder; Norio Takizawa; Peihui Lin; Xianhua Wang; Chunmei Cao; Yan Zhang; Tao Tan; Christopher Ferrante; Hua Zhu; Pin-Jung Chen; Rosalie Yan; Matthew Sterling; Xiaoli Zhao; Moonsun Hwang; Miyuki Takeshima; Chuanxi Cai; Heping Cheng; Hiroshi Takeshima; Rui-Ping Xiao; Jianjie Ma
Journal:  Sci Transl Med       Date:  2012-06-20       Impact factor: 17.956

4.  Lipid-binding properties of TRIM72.

Authors:  Sunghyen Kim; Jeonghwa Seo; Young-Gyu Ko; Young-Duk Huh; Heonyong Park
Journal:  BMB Rep       Date:  2012-01       Impact factor: 4.778

5.  Combinatorial library screening for developing an improved split-firefly luciferase fragment-assisted complementation system for studying protein-protein interactions.

Authors:  Ramasamy Paulmurugan; Sanjiv S Gambhir
Journal:  Anal Chem       Date:  2007-02-13       Impact factor: 6.986

6.  TRIM72 negatively regulates myogenesis via targeting insulin receptor substrate-1.

Authors:  C S Lee; J-S Yi; S-Y Jung; B-W Kim; N-R Lee; H-J Choo; S-Y Jang; J Han; S-G Chi; M Park; J-H Lee; Y-G Ko
Journal:  Cell Death Differ       Date:  2010-02-05       Impact factor: 15.828

7.  Direct observation of individual endogenous protein complexes in situ by proximity ligation.

Authors:  Ola Söderberg; Mats Gullberg; Malin Jarvius; Karin Ridderstråle; Karl-Johan Leuchowius; Jonas Jarvius; Kenneth Wester; Per Hydbring; Fuad Bahram; Lars-Gunnar Larsson; Ulf Landegren
Journal:  Nat Methods       Date:  2006-10-29       Impact factor: 28.547

8.  Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin.

Authors:  Chuanxi Cai; Noah Weisleder; Jae-Kyun Ko; Shinji Komazaki; Yoshihide Sunada; Miyuki Nishi; Hiroshi Takeshima; Jianjie Ma
Journal:  J Biol Chem       Date:  2009-04-20       Impact factor: 5.157

9.  MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling.

Authors:  Jae-Sung Yi; Jun Sub Park; Young-Mi Ham; Nga Nguyen; Na-Rae Lee; Jin Hong; Bong-Woo Kim; Hyun Lee; Chang-Seok Lee; Byung-Cheon Jeong; Hyun Kyu Song; Hana Cho; Yoon Ki Kim; Jae-Seon Lee; Kyong Soo Park; Haksub Shin; Inho Choi; Seung Hee Lee; Woo Jin Park; Shi-Young Park; Cheol Soo Choi; Peihui Lin; Malith Karunasiri; Tao Tan; Pu Duann; Hua Zhu; Jianjie Ma; Young-Gyu Ko
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 10.  Dual function of MG53 in membrane repair and insulin signaling.

Authors:  Tao Tan; Young-Gyu Ko; Jianjie Ma
Journal:  BMB Rep       Date:  2016-08       Impact factor: 4.778

View more
  5 in total

1.  MG53 E3 Ligase-Dead Mutant Protects Diabetic Hearts From Acute Ischemic/Reperfusion Injury and Ameliorates Diet-Induced Cardiometabolic Damage.

Authors:  Han Feng; Hao Shen; Matthew J Robeson; Yue-Han Wu; Hong-Kun Wu; Geng-Jia Chen; Shuo Zhang; Peng Xie; Li Jin; Yanyun He; Yingfan Wang; Fengxiang Lv; Xinli Hu; Yan Zhang; Rui-Ping Xiao
Journal:  Diabetes       Date:  2022-02-01       Impact factor: 9.461

2.  Reduced Sarcolemmal Membrane Repair Exacerbates Striated Muscle Pathology in a Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Brian J Paleo; Kevin E McElhanon; Hannah R Bulgart; Kassidy K Banford; Eric X Beck; Kristina M Sattler; Briana N Goines; Shelby L Ratcliff; Kelly E Crowe; Noah Weisleder
Journal:  Cells       Date:  2022-04-22       Impact factor: 7.666

3.  An MG53-IRS1-interaction disruptor ameliorates insulin resistance.

Authors:  Jun Sub Park; Hyun Lee; Bo Woon Choi; Seonggu Ro; Doyoung Lee; Jeong Eun Na; Jeoung-Ho Hong; Jae-Seon Lee; Bong-Woo Kim; Young-Gyu Ko
Journal:  Exp Mol Med       Date:  2018-06-06       Impact factor: 8.718

4.  Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway via IRS2-proteasome degradation.

Authors:  Hairong Zhao; Jiaming Lu; Furong He; Mei Wang; Yunbo Yan; Binyang Chen; Chenxi Xu; Qiang Wang; Weidong Liu; Wei Yu; Yuemei Xi; Linqian Yu; Tetsuya Yamamoto; Hidenori Koyama; Wei Wang; Chenggui Zhang; Jidong Cheng
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

5.  TRIM72 exerts antitumor effects in breast cancer and modulates lactate production and MCT4 promoter activity by interacting with PPP3CA.

Authors:  Zheng Wang; Haixia Li; Hongxia Wang; Xin Li; Qiong Zhang; Haifang Wang; Kui Li; Yurong Qiu
Journal:  Anticancer Drugs       Date:  2022-06-01       Impact factor: 2.248

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.